Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 18/20 | 0.52 |
| ▸ | CA1 | P00915 | 17/20 | 0.52 |
| ▸ | CA12 | O43570 | 15/20 | 0.52 |
| ▸ | CA7 | P43166 | 10/20 | 0.52 |
| ▸ | CA13 | Q8N1Q1 | 10/20 | 0.52 |
| ▸ | CA6 | P23280 | 9/20 | 0.52 |
| ▸ | CA9 | Q16790 | 9/20 | 0.51 |
| ▸ | CA3 | P07451 | 2/20 | 0.46 |
| ▸ | CA4 | P22748 | 2/20 | 0.46 |
| ▸ | CA5A | P35218 | 2/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.46 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.46 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.46 |
| ▸ | STS | P08842 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7143525 | 0.86 | CA1 (0.58) | CA2CA1CA12CA7CA13 | |
| SCHEMBL23319825 | 0.84 | CA1 (0.48) | CA2CA1CA12CA7CA13 | |
| SCHEMBL3531439 | 0.84 | NEU3 (0.57) | CA2CA1CA12CA7CA13 | |
| SCHEMBL1383113 | 0.84 | CA2 (0.56) | CA2CA1CA12CA7CA13 | |
| SCHEMBL29787230 | 0.84 | NEU3 (0.57) | CA2CA1CA12CA7CA13 | |
| SCHEMBL8103599 | 0.80 | CA2 (0.47) | CA2CA1CA12CA7CA13 | |
| SCHEMBL22015599 | 0.80 | CA2 (0.47) | CA2CA1CA12CA7CA9 | |
| SCHEMBL7944412 | 0.80 | PRKCI (0.51) | CA2CA1CA12CA7CA6 | |
| SCHEMBL6514562 | 0.79 | CA2 (0.46) | CA2CA1CA12CA9STS | |
| SCHEMBL840919 | 0.78 | FLT1 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2176223-B1 | MALONAMIDE DERIVATIVES WITH ANTITHROMBOTIC ACTIVITY | SANOFI SA (FR) | 2013-01-23 | — | — | EP | disclosed |
| EP-2176223-B1 | MALONAMIDE DERIVATIVES WITH ANTITHROMBOTIC ACTIVITY | SANOFI SA (FR) | 2013-01-23 | — | — | EP | disclosed |
| US-8143242-B2 | Malonamide derivatives with antithrombotic activity | SANOFI-AVENTIS (FR) | 2012-03-27 | — | — | US | disclosed |
| US-8143242-B2 | Malonamide derivatives with antithrombotic activity | SANOFI-AVENTIS (FR) | 2012-03-27 | — | — | US | disclosed |
| US-8143242-B2 | Malonamide derivatives with antithrombotic activity | SANOFI-AVENTIS (FR) | 2012-03-27 | — | — | US | disclosed |
| US-20100249101-A1 | MALONAMIDE DERIVATIVES WITH ANTITHROMBOTIC ACTIVITY | SANOFI-AVENTIS (FR) | 2010-09-30 | — | — | US | disclosed |
| US-20100249101-A1 | MALONAMIDE DERIVATIVES WITH ANTITHROMBOTIC ACTIVITY | SANOFI-AVENTIS (FR) | 2010-09-30 | — | — | US | disclosed |
| US-20100249101-A1 | MALONAMIDE DERIVATIVES WITH ANTITHROMBOTIC ACTIVITY | SANOFI-AVENTIS (FR) | 2010-09-30 | — | — | US | disclosed |
| EP-2176223-A1 | MALONAMIDE DERIVATIVES WITH ANTITHROMBOTIC ACTIVITY | Sanofi-Aventis (FR) | 2010-04-21 | — | — | EP | disclosed |
| CN-101687797-A | Malonamide derivatives with antithrombotic activity | SANOFI AVENTIS | 2010-03-31 | — | — | CN | disclosed |
| WO-2009007015-A1 | MALONAMIDE DERIVATIVES WITH ANTITHROMBOTIC ACTIVITY | SANOFI-AVENTIS (FR) | 2009-01-15 | — | — | WO | disclosed |
| WO-2009007015-A1 | MALONAMIDE DERIVATIVES WITH ANTITHROMBOTIC ACTIVITY | SANOFI-AVENTIS (FR) | 2009-01-15 | — | — | WO | disclosed |
| US-4312990-A | HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1982-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249101-A1 | MALONAMIDE DERIVATIVES WITH ANTITHROMBOTIC ACTIVITY | F7, F9, TFPI | CA2 1258/4885CA1 1690/4885CA12 2207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.